Anna Ljung Email and Phone Number
Anna Ljung work email
- Valid
- Valid
- Valid
Anna Ljung personal email
Anna Ljung is a Chief Executive Officer at Moberg Pharma AB. She possess expertise in start ups, pharmaceutical industry, business development, entrepreneurship, biotechnology and 13 more skills.
Moberg Pharma Ab
View- Website:
- mobergderma.se
- Employees:
- 22
-
Chief Executive OfficerMoberg Pharma AbStockholm County, Sweden
-
Chairman Of The BoardBiosergen Jun 2024 - PresentBiosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immunecompromised cancer- transplant- and AIDS patients every year. Biosergen is headquartered in Stockholm and the company’s shares are listed on Nasdaq First North Stockholm (OMX: BIOSGN) -
Chief Executive OfficerMoberg Pharma Ab May 2019 - PresentStockholm, SwedenMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s asset, MOB-015, is a novel topical treatment for onychomycosis, for which the first market approval has recently been obtained. Data from phase 3 clinical trials in more than 800 patients for MOB-015 indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company’s shares are listed on the Small Cap list of the Nasdaq Stockholm (OMX: MOB).
-
Chief Financial OfficerMoberg Pharma Ab 2006 - May 2019
-
Board MemberAddvise Group Ab (Publ) May 2022 - PresentADDvise Group AB (publ) is a leading supplier of equipment and services to healthcare and research facilities. The Group’s subsidiaries are organized into two business areas: Lab and healthcare. Sales are global. The Group has a clear acquisition strategy of increasing shareholder value through growth – both geographically and by product range. ADDvise shares are listed on Nasdaq First North Premier. -
Board MemberSaniona Jan 2018 - PresentSaniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company’s most advanced product candidate, Tesomet™, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. These clinical trials are voluntarily paused due to funding limitations and Saniona is actively exploring partnering opportunities. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com. -
Chairman Of The BoardOncozenge Sep 2020 - Aug 2023Stockholm, Stockholm County, SwedenOncoZenge AB (publ) is a Swedish pharmaceutical company founded in 2020through a spin-off from Moberg Pharma AB. The company collaborates withleading clinicians from Hvidovre Hospital in Denmark. OncoZenge developsbetter products for supportive care of cancer patients. Preparations are underwayfor Phase 3 of BupiZenge®, after leading Phase 2 data for pain relief in patientswith oral mucositis. OncoZenge is headquartered in Stockholm and thecompany’s shares are listed on Nasdaq First North Growth Market (OMX: ONCOZ)
-
Chief Financial OfficerAthera Biotechnologies Ab 2005 - 2006
-
Business ControllerLipopeptide Ab 2005 - 2006
-
FounderIdeas Of Sweden 2004 - 2005
-
FounderBright Brush Ab 2004 - 2005
Anna Ljung Skills
Anna Ljung Education Details
-
Master In Economics And Business Administration
Frequently Asked Questions about Anna Ljung
What company does Anna Ljung work for?
Anna Ljung works for Moberg Pharma Ab
What is Anna Ljung's role at the current company?
Anna Ljung's current role is Chief Executive Officer.
What is Anna Ljung's email address?
Anna Ljung's email address is an****@****ung.biz
What schools did Anna Ljung attend?
Anna Ljung attended Stockholm School Of Economics.
What skills is Anna Ljung known for?
Anna Ljung has skills like Start Ups, Pharmaceutical Industry, Business Development, Entrepreneurship, Biotechnology, Venture Capital, Business Strategy, Medical Devices, Mergers And Acquisitions, Business Planning, Due Diligence, Strategy.
Who are Anna Ljung's colleagues?
Anna Ljung's colleagues are Kerstin Rior, Malin Nilsson, Christina Erixon, Ewa Karlsson, Anders Bröijersén, Kerstin Valinder.
Not the Anna Ljung you were looking for?
-
Anna Ljung
Greater Stockholm Metropolitan Area2zamsos.se, swedbank.se -
Anna Nambord
Greater Malmö Metropolitan Area -
2tele2.com, svk.se -
Anna Ljung
Stockholm2gmail.com, gmail.com
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial